Kohl’s canned its chief executive — hired just four months ago — after an investigation showed that he violated the retailer’s conflict of interest policies, the company said on Thursday.Ashley Buchanan directed Kohl’s to “engage in vendor transactions that involved undisclosed conflicts of interest,” the company said.Kohl’s audit committee oversaw an investigation led by an outside law firm which found that Buchanan had not disclosed the vendor relationships that were deemed inappropriate and for which he ...

星网锐捷（002396.SZ）2025 年一季报点评 公司 25Q1 净利润实现高增，主因去年 24Q1 净利润基数较低，且本季度子公司 锐捷网络实现 1.1 亿元归母净利润。公司当前持有锐捷网络 44.9%股份，其对公 司 Q1 归母净利润贡献较大，系因在 AI 算力需求持续驱动下，互联网数据中心 市场强势增长，面向互联网客户的数据中心交换机产品订单加速交付。公司改善 经营，在费用管控层面有所成效。公司 Q1 毛利率为 66.51%，同比提升 1.27%， 销 售 / 管 理 / 研 发 费 用 率 为 11.97%/5.99%/14.41% ， 同比变动 - 3.6pct/+0.02pct/-2.45pct。 Q1 净利润同比高增，加强 ICT 基建+AI 应用布局 2025 年 05 月 01 日 ➢ 事件：2025 年 4 月 28 日，星网锐捷发布 2025 年一季报。报告期内，公司 实现营业收入 34.85 亿元，同比增长 11.02%；归母净利润 0.42 亿元，同比增长 264.63%；扣非归母净利润 0.30 亿元，同比增长 8,829.05%。 ➢ Q1 业绩同比高增，主因数据中心交换机持 ...

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] - The company will report its financial results for Q1 2025 on May 7, 2025, after market close, followed by a webcast to discuss these results and corporate progress [1] Company Overview - Revolution Medicines is developing a pipeline of RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins [3] - Current clinical candidates include daraxonrasib (RMC-6236), elironrasib (RMC-6291), and zoldonrasib (RMC-9805), with RMC-5127 anticipated to be the next to enter clinical development [3] - The company is also exploring additional RAS(ON) mutant-selective inhibitors such as RMC-0708 (Q61H) and RMC-8839 (G13C) [3]

American States Water (AWR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 7, 2025, might help the stock move higher if these key numbers are better th ...

Cencora (COR) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on May 7, 2025, might help the stock move higher if these key numbers are better than expectation ...

Investment Rating - The report maintains a "BUY" rating for Mindray, indicating a potential return of over 15% over the next 12 months [16]. Core Insights - Mindray's revenue for 2024 is reported at RMB 36.7 billion, reflecting a year-on-year growth of 5.1%, while the attributable net profit is RMB 11.7 billion, up 0.7% year-on-year [1][2]. - The gross profit margin (GPM) has decreased by 1.1 percentage points year-on-year to 63.1%, attributed to pricing pressures on IVD reagents and mid- to low-end medical equipment, as well as weaker IVD testing demand [1]. - Domestic revenue fell by 5.1% year-on-year to RMB 20.3 billion in 2024, with significant declines in the PMLS and MIS segments due to weak hospital procurement [8]. - Overseas revenue grew by 21.3% year-on-year to RMB 16.4 billion, accounting for 44.7% of total revenue, with Asia-Pacific being a key growth driver [8]. - The target price has been adjusted to RMB 249.19 from a previous target of RMB 328.81, reflecting a downside potential of 15.4% from the current price of RMB 215.85 [3]. Financial Summary - For FY24, revenue is projected to grow to RMB 40.2 billion in FY25, with a year-on-year growth rate of 9.4% [2][13]. - The adjusted net profit for FY25 is estimated at RMB 12.3 billion, representing a growth of 6.5% year-on-year [2][13]. - The report indicates a decline in gross profit and operating profit forecasts for FY25E, with revenue expectations revised down by approximately 7.85% [9]. Share Performance - The market capitalization of Mindray is reported at RMB 261.7 billion, with a 52-week high of RMB 324.50 and a low of RMB 211.59 [3]. - The stock has experienced a decline of 20.4% over the past six months [5]. Shareholding Structure - The major shareholders include Smartco Development Limited with 27.0% and Magnifice (HK) Limited with 24.5% [4].

2025年4月21日-25日 本周盘面盘点 0 | 指数表现 上证指数 收盘3295.06，上涨 0.56% 1 2 日均成交额 深圳成指 收盘9917.06，上涨 1.38% 申银万国一级（2021）行业分类中,计算机、汽车、机械设 备净买入额居前。 行业累计净买入额(万元) 计算机 汽车 机械设备 医药生物 通信 基础化工 公用事业 轻工制造 食品饮料 银行 建筑材料 综合 家用电器 纺织服饰 建筑装饰 环保 社会服务 IIIIm 有色金属 农林牧渔 石油石化 煤灰 传媒 商贸零售 美容护理 父进运输 国防军工 钢铁 电力设备 非银金融 电子 -200,000 -100,000 100,000 200,000 0 上海市场 4497亿元，环比减少 2.8% 深圳市场 6671亿元，环比增加 8.7% ८ 行业涨跌 申万一级行业中,25个上涨,6个下跌。 涨幅前三行业:汽车、美容护理和基础化工 跌幅前三行业:食品饮料、房地产和煤炭 全市场两融业务情况 17 概况 截至4月25日 较上周减少 全市场融资融券余额 12.1亿元 18,026.3亿元 较上周减少 融资余额 17,914.7亿元 12.4亿元 较上 ...

Group 1 - The article highlights Paul Franke's extensive experience in trading and investment, emphasizing his successful track record as a stock picker and his innovative investment strategies [1] - Franke's "Victory Formation" system focuses on identifying supply/demand imbalances through specific stock price and volume movements, which are critical for successful stock selection [1] - The "Bottom Fishing Club" articles target deep-value stocks or those showing significant positive technical momentum reversals, while the "Volume Breakout Report" discusses stocks with strong price and volume trends [1] Group 2 - Franke recommends a diversified investment approach, suggesting that investors hold at least 50 well-positioned stocks to achieve consistent outperformance in the stock market [1] - He advises using stop-loss levels of 10% or 20% on individual stock choices to manage risk effectively [1]

Group 1 - Analysts expect Apple to report second-quarter earnings per share of $1.62, an increase from $1.53 in the same quarter last year [1][2] - Expected second-quarter revenue is $94.30 billion, up from $90.75 billion in the previous year, with Apple having beaten revenue estimates in eight straight quarters [2][4] - Benzinga viewers are mixed on Apple's quarterly results, with 30% predicting a beat, 27% predicting mixed results, and 26% predicting a miss [3][7] Group 2 - Analysts and investors are particularly interested in iPhone sales performance and the company's performance in China during the quarter [4] - Commentary on tariffs, the macroeconomic environment, supply chain issues, and future product releases will also be closely monitored [4]

California Resources Corporation (CRC) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be rel ...